F.D.A. Approves Moderna’s mRNA Flu Vaccine

The Food and Drug Administration on Wednesday approved the first mRNA flu vaccine, enabling use of a technology that will make it easier to rapidly target a widely prevalent or particularly virulent strain of the virus.

The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research directed by Health Secretary Robert F. Kennedy Jr., including the cancellation of 22 projects meant to develop vaccines with mRNA technology through the government’s Biomedical Advanced Research and Development Authority.

Initially the F.D.A. had refused to even review Moderna’s application for approval earlier this year, but quickly reversed course after a public outcry. The flu kills more than 300,000 people worldwide each year and was particularly harsh in the 2024-25 season, with an estimated 45,000 deaths in the United States, including at least 297 reported cases in children, according to the Centers for Disease Control and Prevention.

The new vaccine is authorized for people ages 50 to 64. The F.D.A. issued an accelerated approval for adults 65 and older, which allows widespread use and can be converted to a full approval if the results of a follow-up study are deemed acceptable.

Article source: https://www.nytimes.com/2026/08/05/health/mrna-flu-vaccine-moderna.html